CAMBRIDGE, MA - December 15, 2015 - Aurora BioPharma, Inc., a private immuno-oncology company developing CAR T therapy, vaccines, and checkpoint inhibitors for solid tumors, announces it will present at the Biotech Showcase™ Annual Conference to be held in San Francisco on January 11-13, 2016.
The Biotech Showcase™ conference is one of the largest annual international healthcare conferences and will run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11-14, 2016). Investors and biopharmaceutical executives from around the world gather in San Francisco during this second week of January which is widely viewed as setting the tone for the coming year.
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its 8th year, Biotech Showcase is expected to attract upwards of 2,000 attendees.
Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. Aurora's portfolio includes Chimeric Antigen Receptor T-cell therapy (CAR T), vaccines, and checkpoint inhibitor combinations. Aurora's team is comprised of experienced leading research scientists and business professionals with successful track records in the industry.
Glioblastoma is an incurable lethal brain cancer that kills 45,000 people annually in the US and Europe, most well-known has been Senator Ted Kennedy and Vice President Joe Biden’s son. Current Standard of Care consists of surgery, radiation and chemotherapy, with about one year survival. Temozolomide was FDA approved on only a nominal 10 more weeks of survival, or a median survival of 15 months. A Phase I clinical trial with Aurora’s CAR T therapy AU-105 was conducted with 16 Glioblastoma Brain cancer patients, and showed it was well tolerated, no severe adverse events, with strong signs of efficacy, nearly double median survival versus historic median survival. Aurora plans to apply to the FDA for Breakthrough and Orphan Status, as well as plan a randomized multi-site, multi-country Phase II trial of Early Diagnosed Glioblastoma with an endpoint of Overall Survival, and milestone of achieving Fast-Track Drug Approval. Aurora has just started to fund the world’s first Phase I/II intracranial direct injection CAR T trial for refractory recurrent Glioblastoma patients, whose historic median survival is only 32 weeks.
Osteosarcoma is a bone cancer that affects mostly children and adolescents, with poor survival even after amputation of limbs and chemotherapy. A Phase I CAR T trial with AU-105 in 19 Sarcoma (16 Osteosarcoma) patients was completed showing safety with strong signals of efficacy, with 90% of a Partial Response patient’s tumor necrotic, and a patient child alive for three years. A Phase II trial is being planned in combination with PD-1 antibody from a major drug company. Aurora intends in the future to plan a CAR T trial in breast and gastric cancer.
Aurora has an equity interest in MedVax Technologies, that is developing a p53 Dendritic Cell Vaccine, MX-225, that has completed a Phase IIa trial in 54 patients with Small Cell Lung Cancer. A planned Phase I/II trial with MX-225 and a combination of PD-1 from a major drug company is planned in lung cancer, and a Phase II trial is ongoing with MX-225 and Indoximod, an IDO inhibitor drug from NewLink Genetics, in partnership with Roche Holding AG.
For more information, please visit www.aurorabiopharma.net
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
VP, Business Development & Public Relations
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: (617) 674-7718 - Fax: (617) 674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: (305) 371-2301 - Fax: (305) 371-2304
firstname.lastname@example.org - www.aurorabiopharma.net
New Paradigm in Cancer Immunotherapy
Source: Aurora BioPharma, Inc.